IGF-1 peptides and cancer risk: what the evidence says

What did @ryanrussolifts actually say?

Ryan's central claim is that Increlex, the pharmaceutical-grade recombinant IGF-1 drug, is non-selective, meaning it will grow "everything" including organs, intestines, and the jaw, not just skeletal muscle. He also warned that if you have cancer, using it is like "dumping gasoline" on it. He then positioned Increlex as "the most powerful IGF-1 based peptide in existence" and asked whether it outperforms growth hormone or the gray-market IGF-1 peptides commonly sold in the bodybuilding space, like IGF-1 LR3 or DES(1-3) IGF-1.

This is a mix of legitimate pharmacology, reasonable concern, and some hype that deserves unpacking. He is not entirely wrong, but the framing is sloppy enough to mislead people who are already inclined toward self-experimentation.

Does the science back this up?

Mostly yes on the cancer concern, and yes on the non-selectivity. The organ growth claims are grounded in real biology but are being presented without the context of dose, duration, or population.

IGF-1 receptors are expressed throughout the body, not just in muscle tissue. That is not controversial. Firth and Holly (2002, European Journal of Endocrinology) documented IGF-1 receptor distribution across cardiac, intestinal, and skeletal tissue in detail. Increlex, which is mecasermin, activates these receptors systemically because that is how recombinant IGF-1 works, it mimics endogenous IGF-1 without the buffering effects of IGF binding proteins that normally modulate free IGF-1 activity.

On cancer, the association is real but more nuanced than a gasoline metaphor. Elevated endogenous IGF-1 is associated with increased risk for colorectal, breast, and prostate cancers (Chan et al., 1998, Science). However, that is observational data on chronic elevation, not a single exogenous dose. Still, using supraphysiological IGF-1 in someone with existing cancer or precancerous lesions is genuinely concerning and not supported by any safety data in healthy adults.

What did they get wrong (or right)?

He got the biology directionally right but overstated Increlex's market position and left out key context.

Where he's right: Increlex does activate IGF-1 receptors non-selectively. Acromegalic features like jaw enlargement have been documented in long-term IGF-1 excess, both endogenous and exogenous. The FDA-approved label for Increlex lists organomegaly as a known adverse effect in pediatric patients treated for primary IGF-1 deficiency, which is its only approved indication.

Where he went wrong: Calling it "the most powerful IGF-1 based peptide in existence" is not a pharmacological claim you can actually make without comparative efficacy data. Increlex is pharmaceutical-grade recombinant IGF-1. It is not intrinsically more potent than endogenous IGF-1. What it does is bypass binding protein regulation, which changes its pharmacokinetics, not its receptor affinity. Gray-market variants like DES(1-3) IGF-1, which he mentions, actually have higher receptor affinity per molecule than standard IGF-1 LR3 due to their truncated structure (Ballard et al., 1996, Growth Factors). So the "most powerful" framing is questionable at best.

He also openly admits he does not know the comparative data and is asking his audience for writeups, which is an unusual confession for someone presenting themselves as an authority on a product with real medical risk.

What should you actually know?

Increlex is a Schedule-regulated pharmaceutical approved by the FDA only for children with severe primary IGF-1 deficiency. It is not approved for bodybuilding, anti-aging, or performance use in adults. Using it off-label for those purposes is not just legally complicated, it is genuinely poorly studied in that population.

The cancer concern Ryan raises is legitimate enough that it should be taken seriously, not as a certainty, but as a real reason to be cautious. If you have a family history of hormone-sensitive cancers, unknown lesions, or elevated baseline IGF-1, adding exogenous IGF-1 of any kind is a decision that should involve a physician who can order baseline labs and monitor you, not a TikTok comment section.

The comparison to gray-market peptides like IGF-1 LR3 matters too. Those compounds are not FDA-regulated, are often produced in unverified facilities, and have no human safety trials to speak of. Increlex at least has a prescribing label, documented adverse effects, and post-marketing surveillance data from its pediatric use population. That does not make it safe for adults using it recreationally, but it does mean it is a different risk category than the peptides sold in research chemical markets.

If you are interested in IGF-1 modulating approaches under a supervised context, that conversation starts with a clinician reviewing your IGF-1 and GH labs, not with sourcing a pharmaceutical pediatric drug from non-medical channels.